About us

The MEDICINE EVALUATION COMMITTEE (MEDEV) was established in 1998 by representatives of the social health insurance organisations in Austria, Finland, Germany, Luxembourg, The Netherlands, and Switzerland to facilitate informed discussions and exchanges on pharmaceutical policy developments in the EU.

The European Social Insurance Platform (ESIP) in Brussels was commissioned with the role of coordinating the activities of the Committee.

Today MEDEV represents an informal cooperation between 22 national authorities from 18 Member States and Switzerland responsible for the assessment, pricing and reimbursement of medicines in Europe. MEDEV members include national HTA agencies and social health insurers (payers). The Committee meets five times a year, usually at the premises of ESIP in Brussels.

The overarching mission of MEDEV is to further the sustainable provision of medicines to patients who are publicly insured.

 

Cooperation & Exchange

MEDEV provides an informal platform for exchanges between national bodies responsible for the assessment, pricing and reimbursement of medicines to support them in their role at national level. This includes:

  • Rapid assessments of (new) medicinal products of common interest
  • Exchanges on ongoing and planned assessments for reimbursement, methodologies and pharmaceutical policy
  • Review of EU-level activities impacting on national assessment, pricing and reimbursement
  • Timely analyses of drug related trends and innovations, and political and legal initiatives of the European Institutions
 

Expertise

MEDEV provides an informal platform for consultation at EU level, offering specific expertise in the following areas:

 

Collaboration

MEDEV collaborates closely with the following organisations and networks: